351003-57-1 Usage
General Description
5-Chloro-2-Fluorobenzenesulfonamide is a synthetic, organic chemical compound that belongs to the group of sulfonamides. The compound is recognized by its systematic name, the International Union of Pure and Applied Chemistry (IUPAC) as 5-chloro-2-fluorobenzenesulfonamide. It is distinguished by elements of chlorine, fluorine, and a benzenesulfonamide group in its molecular structure. 5-CHLORO-2-FLUOROBENZENESULFONAMIDE is often used in the synthesis of other complex chemical compounds, which are primarily used in pharmaceutical applications. Information regarding its toxicity, environmental impact, and safety measures are mostly derived from the study of similar sulfonamide compounds due to its infrequent usage outside of specialized industries. As every chemical, it should be handled with proper safety measures.
Check Digit Verification of cas no
The CAS Registry Mumber 351003-57-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,1,0,0 and 3 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 351003-57:
(8*3)+(7*5)+(6*1)+(5*0)+(4*0)+(3*3)+(2*5)+(1*7)=91
91 % 10 = 1
So 351003-57-1 is a valid CAS Registry Number.
351003-57-1Relevant articles and documents
Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them
-
Page/Page column 5, (2010/02/17)
Compounds of formula (I): wherein: RCy represents an unsubstituted or substituted cycloalkyl group or cycloalkylalkyl group,R1, R2, R3 and R4, which may be the same or different, each represent a hydrogen or halogen atom or a nitro group; a cyano group; a hydroxy group; an alkoxy group; an alkyl group; an unsubstituted or substituted amino group; a carboxy group; an alkoxycarbonyl group; an aryloxycarbonyl group; an unsubstituted or substituted aminocarbonyl group. Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator.
